Hospital
Alegent Health Bergan Mercy Health System
Alegent Health Bergan Mercy Health System was paid $45.80M by Medicaid between Jan 2018 and Dec 2024, across 419 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoALEGENT HEALTH BERGAN MERCY HEALTH SYSTEM
OMAHA, NE 68124
OMAHA, NE 68124
33aNPI1508941097assigned 10/25/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$45.80M
24GClaims1,701,171
24DCodes billed419
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Nebraska
Rank by total paid#1 of 5
Median peer was paid$1.33M
This provider vs. median35×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 203,561 | $4.89M | |
| 2019 | 197,279 | $5.22M | |
| 2020 | 208,850 | $5.39M | |
| 2021 | 391,054 | $9.67M | |
| 2022 | 395,416 | $10.72M | |
| 2023 | 232,008 | $7.32M | |
| 2024incomplete | 73,003 | $2.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 59,991 | 54,945 | $8.38M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 42,855 | 37,050 | $6.91M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 15,718 | 13,408 | $2.26M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 4.3% | 25,557 | 23,990 | $1.95M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.2% | 10,326 | 7,164 | $1.92M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 7,501 | 6,613 | $1.72M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 23,772 | 8,137 | $1.54M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 13,471 | 12,632 | $1.26M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 6,259 | 5,486 | $1.16M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.4% | 26,686 | 25,011 | $1.10M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 8,741 | 8,220 | $995K |
| 80053 | Comprehensive metabolic panel | 1.5% | 105,790 | 93,672 | $672K |
407 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.4% | 4,591 | $627K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 5,698 | $570K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,619 | $493K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 1,911 | $463K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.0% | 21,605 | $462K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 852 | $448K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 37,242 | $419K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 105,054 | $418K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,872 | $368K |
| G0378 | Hospital observation service, per hour | <1% | 6,276 | $363K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,551 | $337K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 11,820 | $329K |
| 80050 | General health panel | <1% | 26,193 | $324K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,271 | $318K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,784 | $309K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,651 | $301K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,276 | $274K |
| 80061 | Lipid panel | <1% | 41,206 | $260K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 11,486 | $240K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,008 | $210K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,592 | $196K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,386 | $191K |
| 59050 | <1% | 890 | $184K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,707 | $183K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,503 | $178K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 22,411 | $174K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,631 | $168K |
| 84439 | <1% | 14,659 | $168K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 564 | $163K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,650 | $163K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,572 | $161K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,774 | $145K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 896 | $137K |
| 87480 | <1% | 14,477 | $137K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,749 | $123K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,056 | $120K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,827 | $114K |
| 80081 | <1% | 5,069 | $113K | |
| 87660 | <1% | 14,616 | $112K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 742 | $110K |
| 87081 | <1% | 13,692 | $107K | |
| 12001 | <1% | 420 | $105K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 181 | $105K |
| 87510 | <1% | 14,464 | $102K | |
| 97165 | <1% | 2,672 | $97K | |
| 93971 | <1% | 833 | $89K | |
| 84702 | <1% | 7,242 | $86K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,485 | $85K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,328 | $85K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,041 | $84K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,003 | $79K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,003 | $77K |
| 93308 | <1% | 221 | $76K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,769 | $76K |
| 83655 | <1% | 5,060 | $74K | |
| 70496 | <1% | 405 | $74K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 701 | $73K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 627 | $72K |
| 86803 | <1% | 7,422 | $72K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,493 | $69K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 107 | $67K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,847 | $65K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,079 | $64K |
| 76801 | <1% | 1,436 | $62K | |
| 85027 | <1% | 13,436 | $62K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,297 | $60K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 289 | $60K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,228 | $59K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,751 | $57K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 64 | $57K |
| 82607 | <1% | 4,509 | $55K | |
| 96376 | <1% | 5,921 | $54K | |
| 86780 | <1% | 5,043 | $53K | |
| 86787 | <1% | 4,336 | $53K | |
| 87077 | <1% | 8,823 | $52K | |
| 93798 | <1% | 692 | $52K | |
| 93017 | <1% | 178 | $50K | |
| J3490 | Unclassified drugs | <1% | 93,590 | $50K |
| 76642 | <1% | 399 | $49K | |
| 82728 | <1% | 4,896 | $49K | |
| 84484 | <1% | 16,520 | $48K | |
| 83880 | <1% | 7,350 | $46K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 155 | $45K |
| 96367 | <1% | 1,401 | $45K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,174 | $45K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 20,335 | $42K |
| 97116 | <1% | 2,182 | $40K | |
| 71250 | <1% | 571 | $39K | |
| 12011 | <1% | 145 | $39K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 803 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,633 | $36K |
| 83970 | <1% | 1,363 | $36K | |
| 83690 | <1% | 15,503 | $35K | |
| 92526 | <1% | 802 | $34K | |
| 81001 | <1% | 21,501 | $33K | |
| 87186 | <1% | 8,055 | $33K | |
| 81514 | <1% | 358 | $33K | |
| 88304 | <1% | 1,136 | $33K | |
| 86140 | <1% | 5,390 | $32K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 166 | $30K |
| 81025 | <1% | 11,791 | $30K | |
| 82950 | <1% | 5,742 | $30K | |
| 88341 | <1% | 657 | $29K | |
| 86850 | <1% | 2,710 | $28K | |
| 76770 | <1% | 179 | $28K | |
| 74018 | <1% | 1,087 | $28K | |
| 59025 | Fetal non-stress test | <1% | 122 | $28K |
| 82962 | <1% | 16,938 | $27K | |
| 83550 | <1% | 4,545 | $27K | |
| 84153 | <1% | 2,799 | $27K | |
| 73610 | <1% | 1,536 | $27K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,247 | $26K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,824 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 697 | $25K |
| 97161 | <1% | 3,900 | $25K | |
| 0099U | <1% | 206 | $25K | |
| 88342 | <1% | 1,425 | $25K | |
| 73630 | <1% | 1,395 | $24K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 620 | $24K |
| 80074 | <1% | 1,748 | $24K | |
| 93970 | <1% | 190 | $23K | |
| 83540 | <1% | 4,923 | $22K | |
| 80320 | <1% | 623 | $22K | |
| 86480 | <1% | 520 | $21K | |
| 87147 | <1% | 3,905 | $21K | |
| 86900 | <1% | 3,216 | $21K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 169 | $21K |
| 84481 | <1% | 2,155 | $20K | |
| 87070 | <1% | 3,159 | $20K | |
| 73560 | <1% | 1,270 | $19K | |
| 70498 | <1% | 471 | $18K | |
| 83516 | <1% | 1,584 | $18K | |
| 83605 | <1% | 5,286 | $17K | |
| 87340 | <1% | 1,944 | $17K | |
| 73130 | <1% | 1,123 | $17K | |
| 83735 | <1% | 9,666 | $17K | |
| 84146 | <1% | 1,375 | $16K | |
| 85652 | <1% | 4,736 | $16K | |
| 85610 | <1% | 8,930 | $16K | |
| 84403 | <1% | 1,178 | $16K | |
| 87210 | <1% | 4,116 | $16K | |
| 97162 | <1% | 1,719 | $16K | |
| 90715 | <1% | 693 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,966 | $15K |
| 70486 | <1% | 385 | $15K | |
| 81003 | <1% | 11,893 | $15K | |
| 82105 | <1% | 1,067 | $15K | |
| 72100 | <1% | 568 | $15K | |
| 94060 | <1% | 282 | $14K | |
| 92523 | <1% | 389 | $14K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,949 | $14K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 163 | $14K |
| 86038 | <1% | 1,371 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,074 | $12K |
| 82570 | <1% | 3,074 | $12K | |
| 83001 | <1% | 1,150 | $12K | |
| 85379 | <1% | 3,269 | $12K | |
| 82746 | <1% | 1,400 | $12K | |
| 82670 | <1% | 786 | $12K | |
| 73030 | <1% | 941 | $12K | |
| 84144 | <1% | 787 | $11K | |
| 43235 | <1% | 12 | $11K | |
| 73110 | <1% | 738 | $11K | |
| 87040 | <1% | 2,564 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 327 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,642 | $10K |
| 97760 | <1% | 235 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 288 | $10K |
| 82951 | <1% | 828 | $10K | |
| 82803 | <1% | 1,436 | $10K | |
| 80076 | <1% | 1,283 | $10K | |
| 86706 | <1% | 1,034 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,319 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,624 | $9K |
| 94760 | <1% | 3,654 | $9K | |
| 12002 | <1% | 29 | $9K | |
| A4649 | Surgical supply; miscellaneous | <1% | 973 | $8K |
| 85730 | <1% | 3,670 | $8K | |
| 87205 | <1% | 2,890 | $8K | |
| 84703 | <1% | 2,594 | $8K | |
| 82043 | <1% | 2,732 | $8K | |
| 76536 | <1% | 61 | $7K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 127 | $7K |
| 85018 | <1% | 2,464 | $7K | |
| 80164 | <1% | 1,059 | $7K | |
| A9270 | Non-covered item or service | <1% | 28,429 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,081 | $7K |
| 86901 | <1% | 3,655 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 62 | $7K |
| 87338 | <1% | 737 | $7K | |
| 84156 | <1% | 2,939 | $7K | |
| 77080 | <1% | 158 | $7K | |
| 97014 | <1% | 208 | $7K | |
| 84436 | <1% | 773 | $7K | |
| 36591 | <1% | 968 | $7K | |
| 87529 | <1% | 305 | $7K | |
| 87631 | <1% | 62 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,277 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 28 | $6K |
| 84100 | <1% | 6,036 | $6K | |
| 97166 | <1% | 247 | $6K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $6K |
| 84145 | <1% | 1,062 | $6K | |
| 86431 | <1% | 991 | $6K | |
| 80069 | <1% | 847 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,965 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 186 | $6K |
| 87581 | <1% | 188 | $5K | |
| 82677 | <1% | 226 | $5K | |
| 83525 | <1% | 426 | $5K | |
| 83002 | <1% | 645 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,459 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 870 | $5K |
| 84270 | <1% | 497 | $5K | |
| 94726 | <1% | 166 | $5K | |
| 87486 | <1% | 190 | $5K | |
| 84550 | <1% | 1,344 | $5K | |
| 94729 | <1% | 176 | $5K | |
| 82550 | <1% | 1,158 | $5K | |
| 82784 | <1% | 525 | $5K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 15 | $5K |
| 87220 | <1% | 1,802 | $4K | |
| 83986 | <1% | 1,798 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,450 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,547 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,944 | $4K |
| 74174 | <1% | 31 | $4K | |
| 96368 | <1% | 430 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,894 | $4K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 14 | $4K |
| 86376 | <1% | 412 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,584 | $4K |
| 87420 | <1% | 195 | $4K | |
| 86336 | <1% | 227 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,335 | $3K |
| 82952 | <1% | 659 | $3K | |
| 88307 | <1% | 67 | $3K | |
| 86200 | <1% | 407 | $3K | |
| 93925 | <1% | 28 | $3K | |
| 77336 | <1% | 25 | $3K | |
| 84480 | <1% | 327 | $3K | |
| 82150 | <1% | 454 | $2K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 75 | $2K |
| 84165 | <1% | 327 | $2K | |
| 73562 | <1% | 98 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 40,378 | $2K |
| 76870 | <1% | 27 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 104 | $2K |
| 86695 | <1% | 226 | $2K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 913 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,752 | $2K |
| 82533 | <1% | 131 | $2K | |
| 86704 | <1% | 219 | $2K | |
| 85014 | <1% | 1,120 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,621 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 55 | $2K |
| 82330 | <1% | 522 | $2K | |
| C1769 | Guide wire | <1% | 1,242 | $2K |
| 80178 | <1% | 263 | $2K | |
| 96417 | <1% | 287 | $1K | |
| 86696 | <1% | 229 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,956 | $1K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 617 | $1K |
| 80177 | <1% | 153 | $1K | |
| 87536 | <1% | 47 | $1K | |
| 86364 | <1% | 205 | $1K | |
| 76775 | <1% | 57 | $1K | |
| 72141 | <1% | 14 | $1K | |
| 82247 | <1% | 227 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,944 | $1K |
| 99153 | Mod sedat endo service >5yrs | <1% | 216 | $1K |
| 82947 | <1% | 517 | $1K | |
| 83021 | <1% | 74 | $1K | |
| 84425 | <1% | 180 | $1K | |
| 82525 | <1% | 79 | $1K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 5,686 | $1K |
| 73090 | <1% | 82 | $988.70 | |
| 87075 | <1% | 454 | $987.80 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,865 | $979.04 |
| 73590 | <1% | 260 | $937.96 | |
| 29125 | <1% | 25 | $912.69 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 567 | $903.90 |
| 86003 | <1% | 43 | $889.01 | |
| 83615 | <1% | 405 | $871.95 | |
| 72170 | <1% | 180 | $871.22 | |
| 86592 | <1% | 79 | $861.31 | |
| 73502 | <1% | 296 | $843.61 | |
| 84132 | <1% | 887 | $783.76 | |
| 99152 | <1% | 478 | $776.40 | |
| 83721 | <1% | 204 | $722.28 | |
| 83993 | <1% | 73 | $709.57 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 319 | $703.51 |
| 82077 | <1% | 4,189 | $695.61 | |
| 84134 | <1% | 81 | $681.63 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 100 | $630.05 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 786 | $629.58 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16 | $577.60 |
| 73140 | <1% | 115 | $569.81 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,345 | $557.07 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,276 | $547.33 |
| 82565 | <1% | 109 | $485.72 | |
| 88112 | <1% | 44 | $476.10 | |
| 82248 | <1% | 111 | $439.41 | |
| 87046 | <1% | 30 | $418.23 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $401.94 |
| 97129 | <1% | 26 | $383.42 | |
| 87177 | <1% | 37 | $355.45 | |
| 87209 | <1% | 44 | $353.14 | |
| 86141 | <1% | 29 | $338.33 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $331.54 |
| 83520 | <1% | 37 | $327.20 | |
| 86694 | <1% | 29 | $322.71 | |
| 84478 | <1% | 90 | $316.68 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 294 | $298.31 |
| 84630 | <1% | 39 | $289.01 | |
| 80179 | <1% | 1,338 | $267.83 | |
| 87045 | <1% | 30 | $260.54 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 150 | $257.44 |
| 94761 | <1% | 1,004 | $253.36 | |
| 83921 | <1% | 44 | $251.68 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 107 | $250.00 |
| 80143 | <1% | 1,361 | $248.48 | |
| 87427 | <1% | 29 | $245.94 | |
| 72040 | <1% | 16 | $226.56 | |
| 86923 | <1% | 48 | $225.47 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 42 | $210.09 |
| 87493 | <1% | 12 | $209.06 | |
| 96402 | <1% | 17 | $206.46 | |
| 97163 | <1% | 30 | $194.18 | |
| 80185 | <1% | 26 | $191.40 | |
| 73080 | <1% | 42 | $188.98 | |
| 84155 | <1% | 56 | $170.37 | |
| 90686 | <1% | 38 | $168.00 | |
| 84590 | <1% | 26 | $158.54 | |
| 84681 | <1% | 12 | $152.63 | |
| 94664 | <1% | 13 | $151.38 | |
| 88173 | <1% | 15 | $142.71 | |
| 87088 | <1% | 37 | $141.49 | |
| 85660 | <1% | 20 | $128.29 | |
| 86800 | <1% | 15 | $118.42 | |
| 88312 | <1% | 14 | $115.73 | |
| 86235 | <1% | 16 | $115.61 | |
| 84295 | <1% | 593 | $113.84 | |
| 80156 | <1% | 30 | $113.56 | |
| 86334 | <1% | 13 | $112.48 | |
| 85007 | <1% | 57 | $110.54 | |
| 82553 | <1% | 14 | $108.57 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,525 | $105.45 |
| 86708 | <1% | 17 | $97.59 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 737 | $94.71 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 469 | $86.44 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 327 | $83.32 |
| 82310 | <1% | 44 | $79.42 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 799 | $75.93 |
| 89051 | <1% | 39 | $68.75 | |
| 87449 | <1% | 15 | $68.34 | |
| 85045 | <1% | 28 | $53.38 | |
| 84591 | <1% | 26 | $50.53 | |
| 82270 | <1% | 27 | $48.26 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 847 | $42.99 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 16 | $40.65 |
| 86160 | <1% | 14 | $35.71 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 559 | $31.84 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 249 | $29.81 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 27 | $29.12 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 226 | $21.20 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 531 | $14.45 |
| 82010 | <1% | 18 | $13.58 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 14 | $5.49 |
| 94799 | <1% | 46 | $4.68 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 25 | $4.40 |
| G0008 | Administration of influenza virus vaccine | <1% | 14 | $4.03 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 41 | $0.32 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 307 | $0.04 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 765 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 682 | $0.01 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 227 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 109 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 349 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 266 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 357 | $0.00 |
| 80329 | 0% | 83 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 46 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 90 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 61 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 98 | $0.00 |
| G8992 | Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 92 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 27 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 26 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 26 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 35 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 64 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 178 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 119 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 27 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 169 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 488 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 33 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 17 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 16 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 34 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 25 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 33 | $0.00 |
| 73070 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.